CognitrexCancerDigest

Genes2Me, India’s first diagnostic chain to bridge clinical diagnostics with genomics has reinvigorated the preventive healthcare sector in the country. Genes2Me has evolved as a game changer in the field of molecular testing by yielding health statistics of today and suitable lifestyle guidance for a healthy tomorrow.  With a vision to transform genetics for billions across the globe, Genes2Me is continuously moving towards adding value to one’s lifestyle by utilizing their very own genetic blueprint. Their bench translational approach is transforming the way genetics can help people in making informed decisions by scrutinizing their very own genetic makeup.  Genomics, which is the basis of diagnosis at Genes2Me, primarily involves the examination of an individual's set of genes and their interactions through comprehensive analysis. Leveraging the genetic attributes of a person, Genes2Me helps in the dissemination of personalized health and welfare solutions. The state-of-the-

  Breast cancer  /  Cancer Immunology and Immunotherapy  /  Anticancer agents & Biologic therapy  The US Food and Drug Administration (FDA) granted accelerated approval to atezolizumab (TECENTRIQ®, Genentech Inc.) in combination with paclitaxel protein-bound for adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) whose tumours express PD-L1 (PD-L1 stained tumour-infiltrating immune cells [IC] of any intensity covering ≥ 1% of the tumour area), as determined by an FDA-approved test. FDA also approved the VENTANA PD-L1 (SP142) Assay as a companion diagnostic device for selecting TNBC patients for atezolizumab.  Approval was based on IMpassion130 (NCT02425891), a multicentre, international, double-blinded, placebo-controlled, randomised trial that included 902 patients with unresectable locally advanced or metastatic TNBC who had not received prior chemotherapy for metastatic disease. Patients were randomised (1:1) to receive e

Topic :  Lung and other thoracic tumours  /  Cancer Immunology and Immunotherapy  The US Food and Drug Administration (FDA) approved atezolizumab (TECENTRIQ, Genentech Inc.) in combination with carboplatin and etoposide, for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC). Approval was based on IMpower133 (NCT02763579), a randomised (1:1), multicentre, double-blind, placebo-controlled trial in 403 patients with ES-SCLC who received no prior chemotherapy for extensive stage disease and had ECOG performance status 0 or 1. Patients were randomised to one of the following: atezolizumab 1200 mg and carboplatin AUC 5 mg/mL/min on day 1 and etoposide 100 mg/m2 intravenously on days 1, 2 and 3 of each 21-day cycle for a maximum of 4 cycles, followed by atezolizumab 1200 mg once every 3 weeks until disease progression or unacceptable toxicity, or placebo and carboplatin AUC 5 mg/mL/min on day 1 and etoposide 100 mg/m2 intravenously on d